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Abstract
Background: Numerous human genes encode potentially active DNA transposases or recombinases, but our
understanding of their functions remains limited due to shortage of methods to profile their activities on
endogenous genomic substrates.
Results: To enable functional analysis of human transposase-derived genes, we combined forward chemical
genetic hypoxanthine-guanine phosphoribosyltransferase 1 (HPRT1) screening with massively parallel paired-end
DNA sequencing and structural variant genome assembly and analysis. Here, we report the HPRT1 mutational
spectrum induced by the human transposase PGBD5, including PGBD5-specific signal sequences (PSS) that serve as
potential genomic rearrangement substrates.
Conclusions: The discovered PSS motifs and high-throughput forward chemical genomic screening approach
should prove useful for the elucidation of endogenous genome remodeling activities of PGBD5 and other
domesticated human DNA transposases and recombinases.
Background
The human genome contains over 20 genes with similar-
ity to DNA transposases [1]. In addition, transposons are
a major source of structural genetic variation in human
populations [2]. Recently, human THAP9 and PGBD5
have been found to mobilize transposons in human cells
[3, 4]. This discovery raises the possibility that, similar to
the RAG1 recombinase [5], these endogenous human
transposases may catalyze human genome rearrange-
ments during normal somatic cell development or in
distinct disease states. The human genome contains
thousands of genetic elements with apparent sequence
similarity to transposons, but their evolutionary diver-
gence hinders the identification of elements that may
serve as substrates for endogenous human transposases
in general [6], and PGBD5 in particular [4].
In classical genetics, forward chemical genetic screens
have been successfully used to identify spontaneous
mutations in bacteria, yeast and fly [7–10]. Such
approaches use DNA sequencing of cells based on
chemical resistance due to positive or negative pheno-
typic selection. For forward genetics of mammalian and
human cells, mutational analysis of the hypoxanthine-
guanine phosphoribosyltransferase 1 (HPRT1) gene
based on the resistance to toxic purine analogues such
as 8-aza- or 6-thio-guanine (referred to as thioguanine)
has been used; for overview, see [11]. Analysis of HPRT1
has several advantages for forward genetic screens: i)
HPRT1 is on the X chromosome and therefore function-
ally hemizygous, ii) HPRT1 encodes a single domain
globular protein in which alterations of any of its nine
exons are expected to affect enzymatic activity, and iii)
mutations can be selected both positively and negatively,
enabling the specific identification of distinct mutations,
as opposed to general factors controlling cellular gen-
omic stability. Indeed, HPRT1-based forward genetic
screens have been successfully used to characterize
chemical mutagens [12, 13]. In human lymphocytes, this
assay has also been used to identify RAG1-mediated mu-
tations of HPRT1, and to elucidate cryptic recombin-
ation signal sequences [14, 15].
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Here, we sought to develop a forward genetic screen-
ing approach suitable for the elucidation of endogenous
genomic substrates of human DNA transposases and
recombinases. Depending on cell type and presence of
endogenous co-factors, this assay should allow for DNA
transposition and recombination, or alternatively,
nuclease-mediated DNA rearrangements facilitated by
endogenous DNA sequence substrate preferences. Using
negative and positive thioguanine resistance selection,
combined with massively parallel DNA sequencing, we
used HPRT1 screening to investigate the nuclease activ-
ity of PGBD5 on human genomic substrates.
Results
The human HPRT1 gene contains 12 annotated DNA
transposon copies (Additional file 1: Table S1). These
transposons are only distantly related to piggyBac trans-
posons that are evolutionarily related to the potential
substrates of PGBD5 [4]. We hypothesized that under
strong selective pressure, PGBD5 may exhibit enzymatic
activity on sequences in the HPRT1 gene with sufficient
similarity to its endogenous substrates, be they piggy-
Bac-related sequences or not. To test this hypothesis, we
adapted the HPRT1 mutation assay in which cells con-
taining inactivating HPRT1 mutations can be negatively
or positively selected by growth in media containing
hypoxanthine-aminopterin-thymidine (HAT) or thiogua-
nine, respectively [16]. To maximize the sensitivity of
this assay, we used male BJ fibroblasts containing a sin-
gle copy of the X-linked HPRT1 gene [17].
To analyze specific changes induced by human
PGBD5, we generated isogenic cell lines by using lenti-
viral transduction to express GFP-PGBD5 and control
GFP, and confirmed stable and equal transgene expres-
sion using immunoblotting (Fig. 1a). To eliminate
HPRT1 variants induced by spontaneous gene mutations
and enable the specific selection of those induced by
PGBD5, we grew cells in the presence of HAT medium
for 15 doublings [18]. We confirmed that the expression
of GFP-PGBD5 did not alter the intrinsic sensitivity of
BJ cells to thioguanine, as assessed using clonogenic as-
says and analysis of the dose–response to thioguanine by
these cells (Fig. 1b and c). The fractional clonogenic effi-
ciencies of thioguanine resistance induction were 0.027
and 0.028 for cells expressing GFP and GFP-PGBD5, re-
spectively, estimated from the number of thioguanine-
resistant colonies, consistent with the lack of general
mutagenic activity by PGBD5 [12, 13]. To generate cells
with de novo HPRT1 mutations, we grew cells expressing
GFP-PGBD5 or GFP control in the presence of thiogua-
nine for 10 cell divisions, corresponding to approxi-
mately 1 month in culture. To confirm the generation of
Fig. 1 Induction of thioguanine resistance and loss of HPRT1 expression in isogenic cells expressing DNA transposase PGBD5. a Stable expression of
GFP-PGBD5 and control GFP in BJ-hTERT cells, as assessed by Western blotting against GFP; β-actin serves as loading control. b Clonogenic efficiency of
BJ-hTERT cells stably expressing GFP (red) and GFP-PGBD5 (blue) as a function of varying thioguanine concentrations upon thioguanine resistance selection.
c Representative photographs of resistant colonies stained with Crystal Violet. d Thioguanine selection of both GFP and GFP-PGBD5 expressing cells yields
cells that lack HPRT1 activity, as assessed by hypoxanthine-aminopterin-thymidine (HAT) treatment; *** denotes p= 2.2 × 10−5 and 9.6 × 10−4 for the
comparisons between control and thioguanine selected GFP and GFP-PGBD5, respectively. d Thioguanine selection yields thioguanine-resistant cells, as
assessed by cellular ATP luminescence assay of GFP (red) and GFP-PGBD5 (blue) expressing cells, as compared to control cells (gray and black). eWestern
blot for HPRT1 in BJ-hTERT cells expressing GFP and GFP-PGBD5 upon thioguanine selection; β-actin serves as loading control. All error bars represent
standard deviations of 3 biological replicates
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clones with inactivating HPRT1 mutations, we deter-
mined the ability of thioguanine-selected cells to grow in
the HAT medium. We observed more than 3.5-fold de-
crease in the number of viable cells upon HAT treat-
ment, indicating that the majority of the cells had
acquired resistance to thioguanine (Fig. 1d). Consistent
with the inactivation of HPRT1 in these cells,
thioguanine-selected cells exhibited increased resistance
to acute treatment with thioguanine as compared to un-
selected control cells (Fig. 1e). In agreement with this no-
tion, we observed no detectable HPRT1 protein
expression by immunoblotting (Fig. 1f), suggesting that
the majority of thioguanine-resistant cells inactivated
HPRT1 due to mutations that led to the loss of HPRT1
protein expression.
Prior structural studies of HPRT1 gene mutations have
used Southern blotting or cDNA sequencing [19], limiting
the detection and sequence analysis of structural variants
that involve rearrangements of introns and other non-
exonic sequences. To overcome these limitations and en-
able comprehensive and sensitive sequence analysis of re-
arrangements involving potential transposon sequences in
HPRT1, we designed a specific panel of polymerase chain
reaction (PCR) amplicons spanning the entire 43 Kb se-
quence of the human HPRT1 gene, including introns,
exons, and 5′ and 3′ untranslated regions (Fig. 2a and
Additional file 2: Table S2). Massively parallel paired-end
DNA sequencing of the resultant amplicons, producing
millions of sequence reads spanning the HPRT1 locus,
should enable the recovery of rare DNA mutations with-
out the need for single cell cloning that is limited by clonal
fitness, as observed for RAG1-induced HPRT1 mutations
in lymphocytes [20, 21].
To test this prediction, we isolated genomic DNA
from thioguanine-resistant cells expressing GFP-PGBD5
or GFP, and amplified their HPRT1 loci using long-range
PCR (Fig. 2a). Consistent with prior observations of
HPRT1 mutations that were either subclonal or involved
variants not resolvable by electrophoresis [14, 15, 21],
resultant amplicons exhibited no apparent differences in
electrophoretic gel mobility between thioguanine-
resistant and control cells in the presence or absence of
PGBD5 (Fig. 2b). To facilitate the recovery of polyclonal
populations of HPRT1 mutants, we used massively paral-
lel paired-end Illumina DNA sequencing of resultant
genomic amplicons to generate more than 32,000 se-
quence reads at 99 % of nucleotide bases. These data
have been deposited to the Sequence Read Archive
(http://www.ncbi.nlm.nih.gov/sra/, accession number
SRP068848), with the processed and annotated data
available from the Dryad Digital Repository (http://
dx.doi.org/10.5061/dryad.t748p).
To enable comprehensive analysis of PGBD5-induced
HPRT1 mutations, we combined two recently developed
algorithms CRISPResso and laSV that permit the identi-
fication and analysis of both small and large structural
variants in ultra-high coverage DNA sequencing data at
base-pair resolution [22, 23]. We observed that both
GFP and GFP-PGBD5 expressing cells acquired single
nucleotide and small indel mutations of HPRT1 (Fig. 3a).
Consistent with the functional loss of HPRT1 expression
(Fig. 1f ), we observed a relative excess of exonic as com-
pared to intronic variants in thioguanine-resistant cells
(Fig. 3a, right). There was no significant difference in the
frequencies of single nucleotide and small indel muta-
tions of HPRT1 between GFP and GFP-PGBD5 express-
ing cells (Fig. 3a, left). Although both GFP-PGBD5 and
GFP expressing cells developed thioguanine resistance at
least in part due to the acquisition of inactivating single
nucleotide and small indel mutations, this finding
Fig. 2 Massively parallel DNA sequencing combined with PCR amplification for high-resolution mutational analysis of HPRT1. a Schematic of the
human HPRT1 gene structure with vertical bars and horizontal arrows denoting exons and amplicons as numbered. b Photograph of ethidium
bromide-stained and electrophoretically-resolved HPRT1 PCR amplicons of genomic DNA isolated from GFP (red) and GFP-PGBD5 (blue) expressing
cells before (−) and after (+) thioguanine resistance selection
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suggests that PGBD5 activity on human genomic sub-
strates does not directly generate such mutations at the
efficiency required for thioguanine resistance selection.
On the other hand, we observed that cells expressing
GFP-PGBD5 had an excess of complex structural
variants as compared to GFP control cells (Fig. 3c, d and
Table 1). Specifically, we found that PGBD5-expressing
cells contained significantly greater numbers of inversions
in HPRT1 as compared to control GFP cells (p = 0.001,
Poisson test with an exact reference distribution, 95 %
confidence interval 0.14–0.68) and also contained signifi-
cantly greater total numbers of complex structural vari-
ants (p < 0.001, Poisson test with an exact reference
distribution, 95 % confidence interval 0.26–0.71) (Fig. 3c).
Furthermore we observed that some rearrangements
occurred in the absence of thioguanine selection. This
is consistent with the preserved nuclease activity of
PGBD5 which may induce such structural rearrange-
ments in human genomes by virtue of DNA double
strand breaks alone, similar to the RAG1 recombinase
[14, 15]. PGBD5-induced genomic rearrangements in
HPRT1 did not appear to involve annotated human
transposable elements (Fig. 3c), consistent with the
absence of canonical piggyBac-derived transposons
within the human HPRT1 gene [4].
Fig. 3 Comprehensive genomic analysis of HPRT1 mutations reveals PGBD5-mediated induction of complex genomic rearrangements. a (left) Distribution
of the mutational frequency (y-axis) and the location (x-axis) of single nucleotide variants (SNV) and small indels in HPRT1 of cells before (blue) and after
(orange) thioguanine resistance selection. Exons are denoted by gray bars. (right) Comparative analysis of the frequencies of SNVs and indels in HPRT1
before (−) and after (+) thioguanine resistance selection reveals no significant differences between GFP and GFP-PGBD5 expressing cells; * and ** denote
p< 0.05 and p< 0.01 for exonic and intronic variants, respectively (Exonic GFP p= 8.32e-6, exonic GFP-PGBD5 p= 0.09, intronic GFP p= 2.77e-36, intronic
GFP-PGBD5 p= 4.77e-06). b Combined comparative analysis of the frequencies of SNVs and indels in HPRT1 in GFP and GFP-PGBD5 expressing cells
(p= 7.90e-4). c Distribution of the locations of the 5′ ends of complex structural variants in cells before (−) and after (+) thioguanine resistance selection, as
detected by laSV and marked by arrows denoting deletions (brown), inversions (blue), duplications (purple), and translocations (red). Black arrows mark
annotated DNA transposons. d Expression of GFP-PGBD5 leads to induction of complex structural variants before (−) and after (+) thioguanine resistance
selection (Total number of SVs GFP vs. PGBD5, p= 0.001, Poisson test, 95 % confidence interval 0.262–0.713)
Table 1 laSV detects significantly more inactivating mutations
in thioguanine-resistant cells
Control Thioguanine
GFP 0/10 7/17
GFP-PGBD5 12/36 10/29
Values denote the number of inactivating / total variants detected
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Previously, we found that the genomic integration of
transposons by PGBD5 required specific DNA substrate
sequences containing inverted terminal repeats with
GGG terminal motifs [4]. We reasoned that potential
human endogenous PGBD5 substrates in HPRT1 may be
identified by the presence of inverted terminal repeats at
the sequences flanking the breakpoints of the observed
structural variants (specific definition described in the
Methods). Using this approach, we identified 13 terminal
elements flanking the structural variant breakpoints in
the PGBD5-expressing but not in the control GFP cells
(Fig. 4 and Table 2). The identified structural variant
breakpoint sequences exhibited specific motifs in the
PGBD5 but not in the control GFP cells (Fig. 4), as
assessed using sequence entropy analysis and imple-
mented in the MEME algorithm [24, 25]. Consistent
with their thioguanine resistance selection, 2 out of 13
structural variants involving these sequence motifs were
predicted to cause inactivation of HPRT1 by causing ex-
onic deletions, similar to prior studies of RAG1-induced
HPRT1 inactivation [12]. We confirmed that the identi-
fied PGBD5-specific sequence motifs occur in the
HPRT1 gene at approximately the same frequency as the
rest of the human genome, and therefore are not
enriched in our assays simply because of their genomic
distribution (p = 0.066, binomial-test). While they differ
in sequence from the canonical piggyBac-derived
inverted terminal repeats, PGBD5-specific sequence mo-
tifs in HPRT1 are enriched for terminal GGG nucleo-
tides and lack thymines (Fig. 4), in agreement with the
structural requirements observed in previous studies
using synthetic transposon substrates [4]. While these
sequences motifs may constitute specific PGBD5 signal
sequences (PSS) that are associated with PGBD5-
induced genomic rearrangements, it remains to be deter-
mined whether PGBD5 induces a similar variety of gen-
omic rearrangements as part of its endogenous activities,
or alternatively, whether it mediates true DNA transpos-
ition with excision and insertion of specific PSS-
containing inverted terminal repeat mobile elements.
Discussion
In all, our findings indicate that human PGBD5 can in-
duce structural variation and genomic rearrangements of
endogenous human HPRT1 loci. The identification of
potential PGBD5 signal sequences in human genomes
using the HPRT1 forward genetic screen represents a
crucial first step in defining its endogenous genomic
substrates in vertebrates and humans. Consistent with
the distinct evolutionary history and developmental
neuronal expression of PGBD5, identified PSS motifs are
distinct from the recombination signal sequences (RSS)
described for RAG1 in lymphocytes [14, 15]. Import-
antly, identified PSS motifs exhibit only limited similarity
Fig. 4 PGBD5-associated HPRT1 structural variants contain terminal signal sequences. a Analysis of the sequences flanking structural variant
breakpoints demonstrating association of specific signal sequence motifs in cells expressing GFP-PGBD5 (top), but not GFP control (bottom). X-axis
denotes nucleotide sequence logo position, and y-axis denotes information content in bits. Black arrowheads mark the location of the breakpoints.
b Breakpoint sequences of a representative structural variant (deletion bnd_11) showing PSS sequence at both breakpoints of a deletion
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to canonical piggyBac transposons, namely preference
for terminal GGG nucleotides, in support of the distinct
phylogeny of PGBD5 as compared to other piggyBac-de-
rived genes in vertebrates [4]. Since our analysis was
limited to genomic rearrangements of human HPRT1
in BJ fibroblasts the presence of thioguanine selection,
it is possible that PGBD5 may exhibit different se-
quence preferences and remodeling activities in neu-
rons and diseased cells where it is endogenously
expressed. Our analysis did not identify bona fide ‘cut-
and-paste’ DNA transposition in HPRT1, and it remains
to be determined whether PGBD5 catalyzes DNA
transposition of endogenous human mobile elements,
or simply their nuclease-mediated DNA rearrange-
ments. The described PSS motifs now provide essential
templates for future functional studies of PGBD5-
induced genomic remodeling.
Conclusions
Recent discovery of active human THAP9 and PGBD5
DNA transposases, combined with the functional re-
combination activity of RAG1, suggests that other en-
dogenous transposase-derived genes may catalyze as
of yet unknown cell-specific somatic or germ-line re-
arrangements in vertebrates and humans. While their
identification has been substantially empowered by
whole-genome sequencing, determination of their
functional activities has been hindered by the lack of
knowledge of their endogenous substrate sequences.
We expect that the integration of forward genetic
screening with massively parallel DNA sequencing, as
we have done here, and structural variant genome
analysis using methods such as CRISPResso/laSV
should permit the determination of the genome re-
modeling activities of endogenous as well as engi-
neered genome editing enzymes. While leveraging the
advantages of negative and positive selection of
HPRT1 forward genetic screening for specificity, this
approach additionally benefits from improved sensitiv-
ity, enabling the identification of both simple and
complex structural variants at base-pair resolution.
This is limited only by sequencing coverage, without
the need for single cell cloning that may be compro-
mised by cell fitness effects. Finally, we anticipate that
the reported PGBD5 signal sequences will lead to the
elucidation of its function in health and disease.
Methods
Reagents
All reagents were obtained from Sigma-Aldrich, unless
otherwise specified. Synthetic oligonucleotides were syn-
thesized and purified by High Performance Liquid
Chromatography (HPLC) by Eurofins MWG Operon
(Huntsville, AL, USA).
Cell culture
BJ-hTERT cells were obtained from the American Type
Culture Collection (ATCC, Manassas, Virginia, USA).
The identity of all cell lines was verified by Short tandem
repeat analysis (STR) analysis and lack of Mycoplasma
contamination was confirmed by Genetica DNA Labora-
tories (Burlington, NC, USA). Cell lines were cultured in
Dulbecco’s Modified Eagle Medium (DMEM) supple-
mented with 10 % fetal bovine serum and 100 U / ml
penicillin and 100 μg / ml streptomycin in a humidified
atmosphere at 37 °C and 5 % CO2.
Plasmid constructs
Human PGBD5 cDNA (Refseq ID: NM_024554.3) was
cloned as a GFP fusion into the lentiviral vector
pReceiver-Lv103-E3156 (GeneCopoeia, Rockville, MD,
USA). Lentivirus packaging vectors psPAX2 and
pMD2.G were obtained from Addgene [26]. Plasmids
were verified by restriction endonuclease mapping and
Sanger sequencing, and deposited in Addgene (https://
www.addgene.org/Alex_Kentsis/).
Table 2 A putative PGBD5 signal sequence (PSS) can be found at breakpoints of structural variants in PGBD5 expressing cells
Sequences are listed in 5′ to 3′ direction with the breakpoint being on the 3′ end
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Lentivirus production and transduction
Lentivirus production was carried out as described previ-
ously [27]. Briefly, HEK293T cells were transfected using
TransIT with 2:1:1 ratio of the pRecLV103 lentiviral vec-
tor, and psPAX2 and pMD2.G packaging plasmids, ac-
cording to manufacturer’s instructions (TransIT-LT1,
Mirus, Madison, WI). Virus supernatant was collected at
48 and 72 h post-transfection, pooled, filtered and stored
at −80 °C. BJ-hTERT cells were transduced with virus par-
ticles at a multiplicity of infection of 5 in the presence of
8 μg/ml hexadimethrine bromide. Transduced cells were
selected for 2 days with puromycin (5 μg/ml).
Western blotting
To analyze protein expression by Western immunoblot-
ting, 1 million transduced cells were suspended in 340 μl
of lysis buffer (4 % sodium dodecyl sulfate, 7 % glycerol,
1.25 % beta-mercaptoethanol, 0.2 mg/ml Bromophenol
Blue, 30 mM Tris–HCl, pH 6.8). Lysates were cleared by
centrifugation at 16,000 g for 10 min at 4 °C. Clarified ly-
sates (30 μl) were resolved using sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, and electroeluted
using the Immobilon FL PVDF membranes (Millipore,
Billerica, MA, USA). Membranes were blocked using the
Odyssey Blocking buffer (Li-Cor), and blotted using anti-
bodies against GFP (mouse anti-human, 1:500, clone
4B10, Cell Signaling Technology, Beverly, MA), β-actin
(rabbit anti-human, 1:5000, clone 13E5, Cell Signaling
Technology, Beverly, MA), HPRT1 (rabbit anti-human,
1:1000, clone ab10479, Abcam, Cambridge, MA) and β-
actin (mouse anti-human, 1:5000, clone 8H10D10, Cell
Signaling Technology, Beverly, MA). Blotted membranes
were visualized using goat secondary antibodies conju-
gated to IRDye 800CW or IRDye 680RD and the
Odyssey CLx fluorescence scanner, according to manu-
facturer’s instructions (Li-Cor, Lincoln, Nebraska).
Hypoxanthine-aminopterin-thymidine (HAT) medium
selection
HAT medium prepared using the 50× HAT supplement
(Thermo Fisher Scientific) and DMEM medium with 10 %
fetal bovine serum and 100 U / ml penicillin and 100 μg /
ml streptomycin. Media was replaced twice weekly and
cells were grown in the presence of HAT selection for 15
doublings, corresponding to approximately 5 weeks.
Thioguanine selection
Cells were cultured in the presence of 120 ng/ml of 6-
thioguanine for 10 doublings, corresponding to approxi-
mately 4 weeks. Media was replaced twice weekly.
Cell viability and colony formation assays
For cell viability assays, cells were seeded at a density of
200,000 cells per well in 6-well plates (Corning Life
Sciences, Corning, NY, USA). Twenty four hours after
seeding, medium was replaced with HAT medium. The
number of viable cells was counted 2 days after treat-
ment using Trypan Blue staining using the Neubauer
hematocytometer according to the manufacturer’s in-
structions (Thermo Fisher Scientific).
For clonogenic assays, cells were seeded at a density of
10,000 cells per 10-cm dish and treated with 6-
thioguanine (0–1 μg/ml) for 2 weeks. Resultant colonies
were fixed with methanol, stained with Crystal Violet,
and counted manually using a spatial grid.
To assess cell viability of cells after treatment with 6-
thioguanine, cells were seeded into 9-well plates (Thermo
Fisher Scientific, Waltham, MA, USA) at a density of 1000
cells per well. Cell were treated with 6-thioguanine (0–
1 μg/ml) 24 h after seeding. Cell viability was quantified
using the CellTiter-Glo ATP content luminescence based
assay, according to manufacturer’s instructions (Promega,
Madison, WI, USA).
Generation of HPRT1 amplicons
Genomic DNA was extracted from 10 million cells using
the PureLink Genomic DNA Mini Kit according to the
manufacturer’s instructions (Thermo Fisher Scientific).
To exponentially amplify the HPRT1 gene, we designed
primer pairs every 3–8 Kb (Additional file 2: Table S2).
Amplicons were generated using 50 ng of gDNA in
50 μl reaction volumes containing 0.5 μM of primers.
Loci 2 to 8 where amplified using the Phusion Green
High-Fidelity DNA Polymerase (Thermo Scientific,
Waltham, MA, USA) with the following parameters:
98 °C for 30 s, followed by 30 cycles of 98 °C for
10 s, 65 °C for 30 s and 72 °C for 3.5 min, and a
final extension of 72 °C for 3.5 min. Locus 1 was
amplified using the KAPA Long Range HotStart DNA
Polymerase (KAPA Biosystems, Wilmington, MA,
USA) with the following parameters: 94 °C for 3 min,
followed by 40 cycles of 94 °C for 25 s, 60 °C for
15 s and 72 °C for 7 min, and a final extension of 72 °C for
7 min. PCR products were purified using the PureLink
PCR purification kit according to the manufacturer’s in-
structions (Invitrogen Corp., Carlsbad, CA, USA).
Illumina library preparation and sequencing
Equimolar amounts of purified PCR amplicons were
pooled, as measured using fluorometry with the Qubit
instrument (Invitrogen Carlsbad, CA) and sized using
the BioAnalyzer 2100 instrument (Agilent Technologies,
Santa Clara, CA). The sequencing library construction
was performed using the KAPA Hyper Prep Kit (KAPA
Biosystems, Wilmington, MA) and 12 indexed Illumina
adaptors obtained from IDT (Coralville, IO), according
to the manufacturer’s instructions. After quantification
and sizing, libraries were pooled for sequencing on a
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MiSeq (pooled library input at 10 pM) using a 300/300
paired-end run (Illumina, San Diego, CA). A total of
728,000–928,000 paired reads were generated per sam-
ple. The duplication rate varied between 0.22 and
0.27 %. The data reported in this manuscript have
been deposited to the Sequence Read Archive (SRA)
(http://www.ncbi.nlm.nih.gov/sra/, accession number
SRP068848), and the Dryad Digital Repository (http://
dx.doi.org/10.5061/dryad.t748p).
Mutational and structural variant analysis
For the analysis of single nucleotide and small indel mu-
tations, we used the CRISPResso WGS utility from the
CRISPResso software using default parameters [22]. The
analysis was performed on non-overlapping windows of
40 bp spanning the entire HPRT1 gene body. For the
analysis of large structural variants, we used laSV with
the following parameters: -s 30 -k 63 -p 30 [23].
PGBD5 signal sequence analysis
Clustal Omega with default parameters was used for mul-
tiple sequence alignment [24]. PGBD5 signal sequences
were defined using the following criteria: i) sequences
flanking 5′ and 3′ breakpoints demonstrated at least 50 %
identity less than 4 bp from the breakpoints when aligned
to each other in inverted orientation, ii) aligned sequences
contained no single or tandem repeats longer than 5 bp,
and iii) no such alignments were identified at breakpoints
of variants found in GFP control expressing cells. Se-
quence motifs were identified using MEME with default
parameters by referencing alignments in the 5′ to 3′ dir-
ection with the breakpoint at the 3′ terminus [28].
Statistical analysis
Mutational frequencies were calculated as described pre-
viously [18], according to the following formula: Muta-
tional frequency = −Ln(XS / NS) / −Ln(X0 / N0), where N
is the number of cells seeded and X is the number of
colonies formed with (S) and without (0) thioguanine se-
lection. The difference between the number of muta-
tions across samples were compared using a Poisson test
with an exact reference distribution.
Additional files
Additional file 1: Table S1. Annotated DNA transposons in the HPRT1
gene. (DOC 32 kb)
Additional file 2: Table S2. HPRT1 PCR primers and PCR amplicon
locations. (DOC 33 kb)
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